---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-052050"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T05:08:31.664008+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Teva EVP Global R&D Dr. Hafrun Fridriksdottir to depart, search underway

## Summary
- Dr. Hafrun Fridriksdottir, EVP Global R&D, is leaving Teva.
- She will remain in role until June 20, 2022 to assist transition.
- Teva has initiated a search for the next head of Global R&D.
- No successor has been named as of the filing date.

## SEC filing metadata
- accession: 0001193125-22-052050
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312522052050/0001193125-22-052050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312522052050/d268582d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-052050
- JSON: https://secwatch.observer/filing/0001193125-22-052050.json
- Plain text: https://secwatch.observer/filing/0001193125-22-052050.txt

## Key facts
- Executive change
  Hafrun Fridriksdottir departed as Executive Vice President, Global R&D at TEVA PHARMACEUTICAL INDUSTRIES LTD.
  - Action: leaving
  - Role: Executive Vice President, Global R&D
  source text: Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving Teva Pharmaceutical Industries Ltd.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312522052050/0001193125-22-052050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.